| 摘要: |
| 目的 探讨黑升麻制剂治疗妇女绝经后阴道萎缩症状的有效性。方法 选取70例45～60岁、自然绝经1年以上,有绝经后阴道萎缩临床症状的妇女,随机分为两组,观察组40例给予口服黑升麻制剂(莉芙敏)20 mg,每天2次。对照组30例口服碳酸钙D3片1片,每天2次。用药前及用药12周后测定血清卵泡刺激素(FSH)、雌二醇水平及子宫内膜厚度,采用阴道pH值、阴道脱落细胞成熟度评分、阴道萎缩症状评分作为疗效指标,同时记录治疗中发生的不良事件。结果 观察组患者的雌二醇、FSH水平及子宫内膜厚度在治疗前后差异均无统计学意义(P>0.05)。 观察组患者治疗后阴道pH值及阴道脱落细胞成熟度与治疗前相比差异无统计学意义(P>0.05);但阴道萎缩症状评分在治疗12周后为(3.3±0.6)分，与治疗前[(6.0±0.6)分]相比差异有统计学意义(P<0.05)。治疗过程中无严重不良事件发生。结论 黑升麻制剂对绝经后妇女阴道萎缩症状有一定的疗效。 |
| 关键词: 阴道萎缩 绝经后期 黑升麻 莉芙敏 |
| DOI：10.3724/SP.J.1008.2012.00339 |
| 投稿时间：2012-01-29修订日期：2012-03-03 |
| 基金项目: |
|
| Black cohosh improves vaginal atrophy in postmenopausal women |
| SUN Ning-xia,JIN Zhi-jun,JIA Xiao-feng,LI Wen* |
(Department of Obstetrics and Gynecology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
*Corresponding author.) |
| Abstract: |
| Objective To investigate the efficacy of cimicifuga racemosa in reatment of postmenopausal vaginal atrophy. Methods Seventy 45-60 years old women, who had menopause for more than one year and symptoms of postmenopausal vaginal atrophy, were randomly divided into two groups: observation group(n=40) and placebo group(n=30). The observation group was given cimicifuga racemosa (remifemin) 20 mg twice a day for 12 weeks. The placebo group was given one calcium carbonate and vitamin D3 tablet twice a day for 12 weeks. The serum levels of follicle stimulation hormone (FSH) and estradiol (E2) and thickness of endometrium were examined before and after treatment. The vaginal pH value, maturation degree of vaginal exfoliated cells, and atrophic vaginitis evaluating score were used to assess the therapeutic effects. The adverse effects were recorded. Results In the observation group there were no significant differences in FSH and E2 levels and endometrium thickness before and after treatment (P>0.05). The vaginal pH value showed a decreasing tendency and the maturation degree of vaginal exfoliated cells showed an increasing tendency after treatment in the observation group, but there were no significant differences (P>0.05). The atrophic vaginitis evaluating score was significantly higher before treatment compared with that after treatment (6.0±0.6 vs 3.3±0.6, P<0.05). There were no adverse effects during the treatment. Conclusion The remifemin shows certain therapeutic effects for vaginal atrophy in postmenopausal women. |
| Key words: vaginal atrophy postmenopause black cohosh remifemin |
